MARK1 (N-term), 6-40 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-MARK1 (N-term), 6-40 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityMARK1 (N-term), 6-40
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman, mouse
Isotypen/a
Formatpurified
Size0.08 mL, 0.4 mL
Concentrationvial concentration: 2
ApplicationsELISA (EIA), Immunohistochemistry (IHC), Western Blot (WB)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThis MARK1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 6-40 amino acids from the N-terminal region of human MARK1. MARK is a family of kinases that is known for its involvement in establishing cell polarity and in phosphorylating tau protein during Alzheimer neurodegeneration. Expression of MARK causes the phosphorylation of MAPs at their KXGS motifs, thereby detaching MAPs from the microtubules and thus facilitating the transport of particles. This occurs without impairing the intrinsic activity of motors because the velocity during active movement remains unchanged. In primary retinal ganglion cells, transfection with tau leads to the inhibition of axonal transport of mitochondria, APP vesi
Immunogenn/a
Other Names[Serine/threonine-protein kinase MARK1; MAP/microtubule affinity-regulating kinase 1; PAR1 homolog c; Par-1c; Par1c; MARK1 HGNC:6896)]
Gene, Accession #[MARK1], Gene ID: 4139, NCBI: NP_061120.3, UniProt: Q9P0L2
Catalog #MBS9206123
Price$165, $370
Order / More InfoMARK1 (N-term), 6-40 Antibody from MYBIOSOURCE INC.
Product Specific ReferencesDrewes, G., et al., Cell 89(2):297-308 (1997).
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.